Launched in June 2015, the BEAM (Biotech companies in Europe combating AntiMicrobial Resistance) Alliance is a strong Network of approx. 50 small and medium-sized European biopharmaceutical companies committed by developing innovative products to fend-off antibiotic-resistant pathogens.
The BEAM Alliance enables innovation in AMR research by:
- Giving its members a unique voice to propose and support policies and incentives to identified issues, especially in Europe,
- Collaborating with existing community of stakeholders dedicated to implementing tangible solutions,
- Recommending bold incentives that warrant action by policymakers to stimulate innovation.
In 3 years of existence, the BEAM Alliance has become the major contact for policy makers when it comes to the dialogue with European biopharma SME’s developing innovative products to fight against AMR.